Investments in digital health firms are running high at the moment, and a $90 million round for four-year-old Woebot and its artificial intelligence-powered platform for people with mental
Happify Health has launched a prescription digital therapeutic (DTx) – called Ensemble – that can assist the treatment of people with both major depressive disorder and generalised anxiety
Sage Therapeutics and Biogen's antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a falloff in efficacy over time has raised concerns about the commercial po
Researchers in the UK have found that there was a four million rise in prescriptions for antidepressants in England during 2020, adding £139 million to NHS costs.
UK-based Small Pharma has launched on the Toronto's TSX Venture Exchange, raising 58 million Canadian dollars (around £34m) to develop medicines based on N,N-Dimethyltryptamine (DMT) to tre
The active compound in magic mushrooms – psilocybin – seems to be at least as effective as a commercially-available antidepressant in a phase 2 trial, and may work more quickly.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company